## **Humber Area Prescribing Committee**

**Date / Time** 7<sup>th</sup> September 2022 13:00-15:00

Venue MS Teams

Chair Dr Sergio Raise

Notes / Action Points Becci Fory – PA to Chief Pharmacist & Admin Team Leader, HUTH

Quorate: Yes / No No - no clinician representation from HUTH or NLAG and no Chief Pharmacist from NLAG (to circulate approved info to members

for approval prior to next meeting

Attendance Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc)

Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR)

Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee

(CH)

Andrew Karvot – Advanced Clinical and Northern Lincolnshire - Interface Pharmacist (AK)

Weeliat Chong, Chief Pharmacist, Humber Teaching NHS Foundation Trust (WC)

Alberto Ortiz-Moya – Interim Principal Pharmacist MH & LD Services

Joanne Goode - Chief Pharmacist - HUTH (JG)

Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM)

Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Catherine Mannion- Medicines Optimisation Pharmacist, NECS (CM)

Emma Baggaley, Head of Medicines Service, CHCP (EB)

Anna Grocholweska - Mhamdi, Lead Clinical Pharmacist NAViGO (AG)

Apologies Dr Narayana Pothina- Consultant in adult medicine – NLAG

Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS)

Simon Priestley- Chief Pharmacist, NLAG (SP)

Prof A Morice - Professor of Respiratory Medicine, Chair of D&TC HUTH

Agenda Number	Item	Discussion	Action	Lead	Due Date
2022.09.01	Apologies	Noted above			
2022.09.02	Declarations of interest	To be sent to JM			
2022.09.03	Minutes of previous meeting	Accepted as true record			
2022.09.04	Action Tracker	Stakeholder mapping and engagement- JM and LB have discussed briefing, LB already updated mailing list and circulated briefing.	Action complete	JM/LB	
		<ul> <li>Outstanding actions from NLAPC- JM has contacted team involved with ICP pathway groups who have been discussing joint pathway for overactive bladder, to ask if it can be badged as a HUTH document. No response yet.</li> </ul>	JM to chase ICP team		
		<ul> <li>Traffic Light Status- Formulary updated along with red list</li> <li>Work plans- Standing item on agenda</li> </ul>	Action complete		
		Guidelines- JM updated headache guidance and will upload	JM to send to AK and AK to upload	JM/AK	
		Joint Formulary- Chapter 4 currently in progress of being transferred onto net formulary site	Complete transfer to net formulary and remove chapter 4 from HERPC formulary	JM/AK/LS	
		<ul> <li>Ratification of guidelines and SCFs – updating of current guidance not done.</li> </ul>	JM to send to AK before annual leave	JM	
		Ratification of guidelines and SCFs – type 2 diabetes guidance added for discussion at IMOC. And feedback to review all 3 guidelines by all 3 teams – Dr Walton arranging meeting with three teams.			

2022.09.05	Outstanding actions from NLAPC	Mycophenolate- Awaiting funding – not heard back yet	Update next time		
		Inclisiran- JM invited Dr Narayanan to next guideline group to discuss	Update next time	JM	
		ADHD Shared care (NL) – awaiting confirmation of funding	Update next time		
		<ul> <li>Azathioprine shared care for gastro- Shared cared accepted, awaiting clarification around funding.</li> </ul>	Update next time		
		Riluzole shared care- Shared care approved, awaiting confirmation of funding in both NEL/NL as want to launch when funding available at both Places	Update next time		
		Modafinil- Shared care approved, awaiting confirmation of funding in both NEL/NL as want to launch when funding available at both Places	Update next time		
		Atomoxetine liquid- in conjunction with ADHD shared care			
		<ul> <li>Prescribing in gestational diabetes- Discussed at business meeting and currently being looked at standardisation of practice across Northern Lincolnshire places</li> </ul>	Dr Pothina was to address, update next time when present		
		Prescription requests in secondary care- to move over to Humber APC so we have clear information on website about supplies from providers	JM & AK to work on info on this		
		Appropriate prescribing of specialist infant formulae- AK has emailed a community dietitian to ask if they are happy to review and work with north bank on this	Awaiting reply, update next time		
2022.09.06	Outstanding actions from HERPC	<ul> <li>Rheumatology to prepare pathway with rituximab without MTX- still with rheumatology as continuously updating. Awaiting response from Dr Ogunbambi</li> </ul>			

		<ul> <li>KMc and JM to work with CCG to approve MS guideline- JM contacted Gary Hepworth, update of guideline to be sent</li> <li>Hydroxychloroquine – discussed at HUTH D&amp;T around provision of this service, recommendation was to update shared care. Escalated to Patient safety and clinical effectiveness committee</li> <li>JM to confirm prescribing arrangements with specialist team- JM to email</li> <li>JM to update with alternative H2 receptor antagonist and review plan for renal repatriation- JM to go to renal policy meeting to discuss renal repatriation, Tacrolimus and other transplant medicines and their SCFs. Changes to transplant medicine document have been made so this can now be uploaded to</li> </ul>	Awaiting response from rheumatology  JM to contact Gary Hepworth  Update next time  JM to contact Mr Phillips  JM to meet with renal teams	JM	
		HERPC website			
2022.09.07	Traffic Light Status	HUTH D&T: Romosozumab - proposed as RED and to check costing to confirm if decision or recommendation. Post meeting note - Confirmed costing and is a recommendation Faricimab – Approved (recommendation) as RED for IMOC Diroximel fumurate- Approved (decision) as RED NHSE funded  HTFT DTG:	Update formulary/red list		
		Risperidone LA Depot injection – proposed as Amber 1 Paliperidone LA Depot injection – proposed as Amber 1  NLAG M&T: Romosozumab (TA721) – proposed as RED Ranibizumab biosimilar – proposed as RED			
2022.09.08	Feedback from Integrated Medicines Optimisation Committee	RS emailed feedback, diabetes guideline sent as recommendation not approved, they have requested further work to be done across diabetes network to cover all 3 versions of guidelines we currently have.	Noted		

2022.09.09	Work plans	<ul><li>a) Joint formulary alignment</li><li>b) Shared care frameworks</li><li>c) Guidelines</li></ul>	Ongoing		
2022.09.10	Ratification of guidelines and SCFs	a) Acute Diabetic Foot Emergency Guidance for Primary Care Practitioners	Ongoing		
2022.09.11	Ratification of joint formulary	Chapter 2 – not discussed due to time constraints.	For next meeting		
2022.09.12	NICE guidance and technology appraisal process	Need to clarify NICE guidance and the different processes in trusts around approval with NICE TAs. Don't want to change our processes within the trust but we need to ensure that the formulary is correct around commissioning. Cannot add TAs to formulary until we have discussed them at APC and we also need to ensure we are looking at them properly within the RTDC documentation, within APC.			
2022.09.13	RTDC updates	a) May 22 b) June 22	Noted		
2022.09.14	Minutes from subcommittees	a) Joint formulary subcommittee     b) Guideline subcommittee	Attached for info only		
2022.09.15	Additional minutes for information	a) HUTH D&TC (June 22) b) HFT DTG (nil this month) c) NLAG M&T (July 22) d) NYY APC (nil this month)	Attached for info only		
2022.09.16	AOB	Phytomenadione – NL formulary for this and all vitamin K is on there but not TLS classified at APC. Meds op support queried classification to enable prescribing. AK and JM suggested TLS green. JM would like Menadiol TLS Amber 1	To update formulary	AK to update formulary	
		APC meetings to be moved to monthly for the next 3 months and review at that point. Guideline and joint formulary to alternate.	LS to send out updated meetings	LS to update meetings	
2022.09.17	Date of next meeting	5 <sup>th</sup> October 13.00 – 15.00			